CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
designed to evaluate the efficacy, safety, and tolerability of two doses of CT1812 compared to placebo in participants diagnosed with early Alzheimer's...
Phase 2
Irvine, California, United States and 29 other locations
This is a randomized, double-blind, sham-controlled, adaptive-design pivotal study of sensory stimulation in subjects with mild to moderate Alzheimer's...
Fullerton, California, United States and 67 other locations
The reason for this study is to collect safety and efficacy information regarding the study drug remternetug in participants with early Alzheimer's...
Phase 3
Encino, California, United States and 75 other locations
This study is designed to evaluate safety and efficacy of fosgonimeton (ATH-1017) in the treatment of mild to moderate Alzheimer's disease...
Phase 2, Phase 3
Encino, California, United States and 89 other locations
efficacy of investigational products in participants with an Alzheimer's disease-causing mutation by determining if treatment with ...
Phase 2, Phase 3
Los Angeles, California, United States and 37 other locations
To assess the safety, tolerability, biomarker, cognitive, and clinical efficacy of investigational products in participants with an Alzheimer's...
Phase 2, Phase 3
Los Angeles, California, United States and 37 other locations
This 52-week, open-label extension study is to evaluate the long-term safety and tolerability of ACP-204 in subjects with ADP.
Phase 3
Costa Mesa, California, United States of America and 5 other locations
progression of AD, as compared to no stimulation (OFF), by measuring baseline (pre-implantation) to 12-month change in the integrated Alzheimer's...
Los Angeles, California, United States and 20 other locations
This is a master protocol for 3 independent, seamlessly enrolling, multicenter, randomized, double-blind, placebo-controlled, parallel-group studies...
Phase 2, Phase 3
Anaheim, California, United States of America and 59 other locations
is superior to placebo on change from baseline of the Preclinical Alzheimer Cognitive Composite 5 (PACC5) at 216 weeks of treatment (A45 Tri...
Phase 3
Los Angeles, California, United States and 117 other locations
Clinical trials
Research sites
Resources
Legal